芪明颗粒联合重组人表皮生长因子滴眼液治疗糖尿病患者青光眼白内障联合手术后眼干燥症疗效观察  

Effect of Qiming granule combined with recombinant human epidermal growth factor eyedrops in the treatment of xerophthalmia after combined operation of glaucoma and cataract in patients with diabetes mellitus

作　　者：郭宇[1] 申勇智 刘丽娜 王丽坤[1] 杜鹏 GUO Yu;SHEN Yongzhi;LIU Lina;WANG Likun;DU Peng(Department of Ophtalmology,the Second Affiliated Hospital of Hebei North University,Zhangjiakou 075100,Hebei Province,China;Department of Ophthalmology and Otorhinolaryngology,Xuanhua District People's Hospital in Zhangjiakou City,Zhangjiakou 075100,Hebei Province,China;Department of Ophtalmology,the Fourth Hospital of Zhangjiakou City,Zhangjiakou 075000,Hebei Province,China)

机构地区：[1]河北北方学院附属第二医院眼科,河北张家口075100 [2]张家口市宣化区人民医院五官科,河北张家口075100 [3]张家口市第四医院眼科,河北张家口075000

出　　处：《新乡医学院学报》2021年第2期124-128,共5页Journal of Xinxiang Medical University

基　　金：河北省科技厅健康医疗与生物医药专项重点研发计划项目(编号:172777116)。

摘　　要：目的探讨芪明颗粒联合重组人表皮生长因子滴眼液治疗糖尿病患者青光眼白内障联合手术后眼干燥症的临床效果。方法选择2014年4月至2019年10月于河北北方学院附属第二医院眼科行青光眼白内障联合手术后发生眼干燥症的75例(75眼)糖尿病患者为研究对象,根据治疗方法将患者分为A组、B组和C组,每组25例。A组患者给予妥布霉素地塞米松滴眼液和玻璃酸钠滴眼液等常规治疗;在常规治疗基础上,B组患者给予重组人表皮生长因子滴眼液治疗,C组患者给予芪明颗粒和重组人表皮生长因子滴眼液治疗;3组患者均治疗4周。治疗前及治疗1、2、3、4周对患者进行眼干燥症症状评分和角膜荧光素染色(CFS)评分,治疗前及治疗4周后测量患者基础泪液分泌量和泪膜破裂时间,治疗4周后评定3组患者临床治疗效果。结果治疗前3组患者的眼干燥症症状评分比较差异无统计学意义(P>0.05);3组患者治疗1、2、3、4周后眼干燥症症状评分均显著低于治疗前(P<0.05);治疗1、2、3、4周,B组和C组患者眼干燥症症状评分均显著低于A组,C组患者眼干燥症症状评分显著低于B组(P<0.05)。治疗前3组患者泪膜破裂时间和基础泪液分泌量比较差异无统计学意义(P>0.05);3组患者治疗4周后泪膜破裂时间和基础泪液分泌量显著大于治疗前(P<0.05);治疗4周后,B组和C组患者泪膜破裂时间和基础泪液分泌量显著大于A组,C组患者泪膜破裂时间和基础泪液分泌量显著大于B组(P<0.05)。治疗前3组患者CFS评分比较差异均无统计学意义(P>0.05);3组患者治疗1、2、3、4周后CFS评分显著低于治疗前(P<0.05);治疗1、2、3、4周后3组患者CFS评分比较差异无统计学意义(P>0.05)。A组、B组和C组患者总有效率分别为84.00%(21/25)、92.00%(23/25)、100.00%(25/25),C组患者治疗总有效率显著高于A组和B组(χ^(2)=10.327、5.625,P<0.05),B组患者治疗总有效率显著高于A�Objective To investigate the clinical effect of Qiming granule combined with recombinant human epidermal growth factor eyedrops in the treatment of xerophthalmia after combined operation of glaucoma and cataract in patients with diabetes mellitus.Methods Seventy-five patients(75 eyes)with diabetes mellitus complicated with xerophthalmia after combined operation of glaucoma and cataract in the Second Affiliated Hospital of Hebei North University from April 2014 to October 2019 were selected as the research subjects,and the patients were divided into group A,group B and group C according to the treatment methods,with 25 cases in each group.The patients in the group A were treated with conventional treatment such as tobramycin and dexamethasone eyedrops and sodium hyaluronate eyedrops.On the basis of conventional treatment,the patients in the group B were treated with recombinant human epidermal growth factor eyedrops,while the patients in the group C were treated with Qiming granule and recombinant human epidermal growth factor eyedrops.The patients in the three groups were treated for 4 weeks.The symptom score of xerophthalmia and the corneal fluorescein staining(CFS)score of the patients were performed before treatment and after 1,2,3,4 weeks of treatment.The basic lacrimal secretion and breakup time of tear film were measured before and after 4 weeks of treatment.The clinical effects of the patients in the three groups were evaluated after 4 weeks of treatment.Results There was no significant difference in the symptom score of xerophthalmia among the three groups before treatment(P>0.05).The symptom score of xerophthalmia of the patients after 1,2,3 and 4 weeks of treatment was significantly lower than that before treatment in the three groups(P<0.05).After 1,2,3 and 4 weeks of treatment,the symptom score of xerophthalmia of the patients in the group B and group C was significantly lower than that in the group A,and the symptom score of xerophthalmia of the patients in the group C was significantly lower than th

关 键 词：糖尿病 眼干燥症 芪明颗粒 重组人表皮生长因子滴眼液 

分 类 号：R779.6[医药卫生—眼科] R587.2[医药卫生—临床医学]